Corvus Pharmaceuticals (NASDAQ:CRVS) versus Enanta Pharmaceuticals (NASDAQ:ENTA) Head-To-Head Contrast

Enanta Pharmaceuticals (NASDAQ:ENTA) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Earnings & Valuation

This table compares Enanta Pharmaceuticals and Corvus Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$71.96 million	2.75	-$133.82 million	($5.45)	-1.72
Corvus Pharmaceuticals	N/A	N/A	-$27.03 million	($0.93)	-9.69

Corvus Pharmaceuticals has lower revenue, but higher earnings than Enanta Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 13.6% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Enanta Pharmaceuticals and Corvus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-160.27%	-63.75%	-27.09%
Corvus Pharmaceuticals	N/A	-70.71%	-45.90%

Risk & Volatility

Enanta Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Enanta Pharmaceuticals and Corvus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1	0	2	1	2.75
Corvus Pharmaceuticals	0	0	3	1	3.25

Enanta Pharmaceuticals currently has a consensus price target of $19.67, suggesting a potential upside of 110.34%. Corvus Pharmaceuticals has a consensus price target of $12.83, suggesting a potential upside of 42.43%. Given Enanta Pharmaceuticals’ higher probable upside, research analysts plainly believe Enanta Pharmaceuticals is more favorable than Corvus Pharmaceuticals.

Summary

Corvus Pharmaceuticals beats Enanta Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.